

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Paul Grandinetti on 10-14-10.

The application has been amended as follows:

Cancel claims 11 and 13.

2. The following is an examiner's statement of reasons for allowance:

3. Claims 1, 3-10 and 12 have been canceled.

4. Instant claims are directed to a composition and a method of treating atopic dermatitis and psoriasis. While prior art teaches the claimed adrenocorticosteroid, cyclodextrin, dextran, pullulan and xyloglucan for atopic dermatitis and psoriasis, the prior art of record does not teach the specific combination of the claimed amounts of trehalose with the above claimed ingredients and instead teaches very low amounts (0.00025%) as a bath ingredient. The prior art of record does not provide any motivation to increase the concentration of trehalose by several folds i.e., from 0.00025% (of prior art) to the claimed 0.5% -55%. Further, applicants have provided evidence that the therapeutic value of adrenocortical steroid is enhanced by xyloglucan, trehalose, laminaran, krestin, cyclodextrin, pullulan or dextrin and pectin.

5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lakshmi S. Channavajjala whose telephone number is 571-272-0591. The examiner can normally be reached on 9.00 AM -5.30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sharmila G. Landau can be reached on 571-272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Lakshmi S Channavajjala/
Primary Examiner, Art Unit 1611

Application/Control Number: 10/516,657

Page 4

Art Unit: 1611